On embarking on this study, our hypothesis was that through both of these mechanisms, the Thrombin-PAR1 coagulation/inflammation axis plays a significant role in barrier loss in CM, and that adjunct treatments targeting this might alleviate mortality or post-CM neurological sequelae in CM. This evidence concerns the gene F2R and cutaneous mastocytosis.